What they were paid
Inozyme Pharma Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | $62,250 | $0 | $123,200 | $0 | $185,450 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inozyme Pharma, Inc. DEF 14A filed April 29, 2025, accession 0000950170-25-060198, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2024Inozyme Pharma pays directors a $40,000 cash retainer and $123,200 in equity.
Committees
FY2024 · as the proxy prints themAudit · Nominating/Governance (Chair) · Research and Development (Chair)
The rest of the Inozyme Pharma board
FY2024 · as the company reported each| Director | Role | FY2024 total |
|---|---|---|
| Axel Bolte | Director | $164,093 |
| Douglas A. Treco | Chair of the Board | $0 |
| Edward Mathers | Independent Director | $170,950 |
| Erik Harris | Independent Director | $282,286 |
| Lynne Sullivan | Independent Director | $176,950 |
| Reinaldo Diaz | Lead Independent Director | $191,325 |
| Robert Hopfner | Independent Director | $166,950 |
| Sarah Bhagat | Independent Director | $171,966 |
The full Inozyme Pharma compensation record
free company briefThis page is one director within Inozyme Pharma's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat